UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 17, 2019
RAFAEL HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 1-38411 | 82-2296593 | ||
(State or other jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
520 Broad Street Newark, New Jersey |
07102 | |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (212) 658-1450
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On January 23, 2019, Rafael Holdings, Inc. (the “Company”) issued the attached press release (the “Release”) relating to the purchase of an additional equity stake in Rafael Pharmaceuticals, Inc. (“Rafael Pharmaceuticals”). Following the purchase, the Company, through certain subsidiaries, owns securities representing 51.0% (of which 12.3% is beneficially held by co-investors in subsidiaries of the Company) of the outstanding capital stock of Rafael Pharmaceuticals and 39.5% (of which 9.5% is beneficially held by co-investors in subsidiaries of the Company) of the capital stock of Rafael Pharmaceuticals on a fully diluted basis (excluding the remainder of a warrant to purchase additional capital stock of Rafael Pharmaceuticals held by a subsidiary of the Company). A copy of the Release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
The Company is furnishing the information contained in this Report, including Exhibit 99.1, pursuant to Item 7.01 of Form 8-K promulgated by the Securities and Exchange Commission (the “SEC”). This information shall not be deemed to be “filed” with the SEC or incorporated by reference into any other filing with the SEC.
Item 8.01 Other Events.
The information contained in Item 7.01 above is incorporated herein by reference into this Item 8.01.
Item 9.01 Financial Statements and Exhibits.
(d) | Exhibits. |
Exhibit No. | Document | |
99.1 | Press Release, dated January 23, 2019. |
1 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
RAFAEL HOLDINGS, INC. | ||
By: | /s/ David Polinsky | |
Name:
David Polinsky Title: Chief Financial Officer |
Dated: January 23, 2019
2 |
EXHIBIT INDEX
Exhibit Number | Document | |
99.1 | Press Release, dated January 23, 2019. |
3 |
Exhibit 99.1
Rafael Holdings Acquires Majority Stake in Rafael Pharma
Rafael Pharma will utilize the investment to further advance the clinical development of devimistat (CPI-613®)
NEWARK, NJ – January 23, 2019: Rafael Holdings, Inc. (NYSE American: RFL) today announced that it has purchased a majority stake in Rafael Pharmaceuticals, Inc., (Rafael Pharma). Rafael Pharma is a clinical stage, metabolic oncology-therapeutics company developing innovative, highly selective and well tolerated anti-cancer agents.
Building on its prior investments, Rafael Holdings further exercised its warrant and converted other interests. The total investment to date from Rafael Holdings in Rafael Pharma securities, inclusive of cash, debt instruments, conversion of notes and contributions from minority beneficial holders, has increased to $66.7 million. The Company and its subsidiaries now hold 51.0% of the outstanding stock of Rafael Pharma. (Exclusive of minority beneficial holders’ interests, Rafael Holdings now holds 38.7% of the outstanding equity in Rafael Pharma).
Howard Jonas, Chairman and CEO of Rafael Holdings, said, “We continue to invest in Rafael Pharma to support the promising clinical development of its lead drug, devimistat (CPI-613®), as well as other Rafael Pharma agents now in pre-clinical development that have been discovered from its Altered Metabolism Directed platform. As the two companies further align, we strengthen our capacity to leverage their complementary attributes for mutual benefit.”
“We very much appreciate the continuing investment by Rafael Holdings,” said Sanjeev Luther, President and Chief Executive Officer of Rafael Pharmaceuticals. “With this support, we believe we are well positioned to advance our clinical program and products in our development pipeline including two recently initiated, pivotal phase III studies of our lead drug, devimistat (CPI-613®) for patients battling metastatic pancreatic cancer and relapsed AML.”
Rafael Pharma’s first-in-class clinical lead compound, devimistat, is being evaluated in multiple Phase I, I/II, and III clinical studies. Devimistat has been granted orphan drug designation for the treatment of patients with pancreatic cancer, acute myeloid leukemia (AML), peripheral T-cell lymphoma (PTCL), Burkitt lymphoma and myelodysplastic syndromes (MDS) by the US Food and Drug Administration, and for patients with pancreatic cancer and AML by the European Medicines Agency (EMA).
Rafael Holdings and its subsidiaries had previously invested in debt securities of Rafael Pharma and partially exercised the warrant for other shares of Series D Preferred Stock. The warrant is exercisable for up to a 56% of the fully diluted equity of Rafael Pharmaceuticals.
All statements above that are not purely about historical facts, including, but not limited to, those in which we use the words “believe,” “anticipate,” “expect,” “plan,” “intend,” “estimate,” “target” and similar expressions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. While these forward-looking statements represent our current judgment of what may happen in the future, actual results may differ materially from the results expressed or implied by these statements due to numerous important factors. Our filings with the SEC provide detailed information on such statements and risks, and should be consulted along with this release. To the extent permitted under applicable law, Rafael Holdings, Inc. assumes no obligation to update any forward-looking statements.
About Rafael Holdings, Inc.:
Rafael Holdings holds commercial real estate assets and interests in two clinical stage pharmaceutical companies. The real estate holdings consist of properties in Newark and Piscataway, New Jersey and Jerusalem, Israel. The pharmaceutical holdings comprise majority interests in Rafael Pharmaceuticals, Inc., and Lipomedix Pharmaceuticals Ltd. Both are focused on development and commercialization of drugs in the oncology space. For more information, visit www.rafaelholdings.com
Contact:
Rafael Holdings
David Polinsky
Chief Financial Officer
P: (212) 658-1450
E: invest@rafaelholdings.com
# # #
&.4 Y =0V#Z\T)BL9,$EUK'A*VFL#_9EQ-!')$I3(C/!"
MD*<8[<'M4&B:+=VFL7>I74=E:F>)8S;V.2C$$GS&) RW..G3N>W0T47'8H
MZ;